Compared to the control group, the ASH1L-depleted bone tumors showed a remarkable reduction in lipid-associated TAM (MC5), proliferating TAMs (MC7), and angiogenic TAMs (M4), along with a dramatic increase in monocyte/TAM intermediate cells (MC3). This evidence concerns the gene ASH1L and bone neoplasm.